By Karen Roman
Agendia, Inc. said it will present data to assess treatment decisions on patients with early-stage breast cancer at the San Antonio Breast Cancer Symposium 2024.
The studies will show how genomic testing can predict patients’ response to chemotherapy, among others, the company stated.
“These data significantly enhance our understanding of MammaPrint and BluePrint’s growing clinical applications,” said William Audeh, Agendia’s Chief Medical Officer.
Contact:
